MEDICATION DEVELOPMENT FOR COCAINE ABUSERS

针对可卡因滥用者的药物开发

• 批准号: 8357378
• 负责人: MICHAEL J KUHAR
• 金额: $ 3.29万
• 依托单位: EMORY UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-08-01 至 2012-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8357378
• 关键词: Cocaine; Development; Funding; Grant; Human; Laboratories; National Center for Research Resources; Pharmaceutical Preparations; Phase I Clinical Trials; Primates; Principal Investigator; Research; Research Infrastructure; Resources; Source; Testing; Toxic effect; United States National Institutes of Health; Writing; cost

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. RTI-336, a compound first tested and characterized in our laboratories, has been approved for Phase I clinical trials in humans. As of this writing, no toxic effects were found that preclude further study, and additional studies are planned in humans. RTI-336 would be a new medication for cocaine addicts.

这个子项目是许多利用资源的研究子项目之一 由NIH/NCRR资助的中心拨款提供。子项目的主要支持 而子项目的主要调查员可能是由其他来源提供的， 包括其它NIH来源。 列出的子项目总成本可能 代表子项目使用的中心基础设施的估计数量， 而不是由NCRR赠款提供给子项目或子项目工作人员的直接资金。 RTI-336是一种首次在我们实验室进行测试和表征的化合物，已被批准用于人体I期临床试验。 截至撰写本文时，未发现任何毒性作用，无法进行进一步研究，计划在人体中进行其他研究。 RTI-336将成为可卡因成瘾者的新药物。